Evidence map›Paper›PMID 39738035›Full record

ArticleNature communications2024

Colon-targeted engineered postbiotics nanoparticles alleviate osteoporosis through the gut-bone axis.

Tingting Yu, Rushui Bai, Zeming Wang, Yuting Qin, Jingwei Wang, Yaohua Wei, Ruifang Zhao, Guangjun Nie, Bing Han

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Links between bone fractures and the gut microbiota.Nature reviews. Endocrinology · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. PasteurizedFrontiers in immunology · 2026
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tingting Yu *Department of Orthodontics, Peking University School and Hospital of Stomatology, Beijing, China.
Rushui Bai *Department of Orthodontics, Peking University School and Hospital of Stomatology, Beijing, China.ORCID 0000-0002-1718-7233
Zeming Wang *CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center of Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
Yuting Qin *CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center of Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
Jingwei WangDepartment of Orthodontics, Peking University School and Hospital of Stomatology, Beijing, China.ORCID 0000-0001-6508-934X
Yaohua WeiCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center of Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
Ruifang ZhaoCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center of Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China. zhaorf@nanoctr.cn.ORCID 0000-0002-2735-2159
Guangjun NieCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center of Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China. niegj@nanoctr.cn.ORCID 0000-0001-5040-9793
Bing HanDepartment of Orthodontics, Peking University School and Hospital of Stomatology, Beijing, China. kqbinghan@bjmu.edu.cn.ORCID 0000-0003-4584-1092

Funding

Beijing Municipal Science and Technology Commission Z211100002921066Beijing Nova Program 202304584382National Natural Science Foundation of China (National Science Foundation of China) 52373123National Natural Science Foundation of China (National Science Foundation of China) 52473120National Natural Science Foundation of China (National Science Foundation of China) U21A2055
6 · The paper itself

Abstract

The potential for mitigating intestinal inflammation through the gut-bone axis in the treatment of osteoporosis is significant. While various gut-derived postbiotics or bacterial metabolites have been created as dietary supplements to prevent or reverse bone loss, their efficacy and safety still need improvement. Herein, a colon-targeted drug delivery system is developed using surface engineering of polyvinyl butyrate nanoparticles by shellac resin to achieve sustained release of postbiotics butyric acid at the colorectal site. These engineered postbiotics nanoparticles can effectively suppress macrophage inflammatory activation, modulate the redox balance, and regulate the composition of the gut microbiota, thereby restoring epithelial barriers, inhibiting bacterial invasion, and down-regulating pro-inflammatory responses. As a result, the remission of systemic inflammation is accompanied by a rebalancing of osteoblast and osteoclast activity, alleviating inflammatory bowel disease-related and post-menopausal bone loss. Specifically, the treatment of engineered postbiotics nanoparticles can also improve the quality and quantity of bone with restoration of deteriorative mechanical properties, which indicating a therapeutic potential on fracture prevention. This study provides valuable insights into the gut-bone axis and establishes a promising and safe therapeutic strategy for osteoporosis.

Indexed as

ColonGastrointestinal MicrobiomeNanoparticlesOsteoporosisAnimalsBone and BonesButyric AcidDrug Delivery SystemsFemaleHumansInflammationInflammatory Bowel DiseasesMiceMice, Inbred C57BLOsteoblastsOsteoclastsButyric Acid

Identifiers

PMID39738035
PMCPMC11686147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.